[Second Korean Guidelines for the Management of Crohn's Disease].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Corporate Authors:
      IBD Study Group of the Korean Association for the Study of the Intestinal Diseases
    • Source:
      Publisher: Korean Society of Gastroenterology Country of Publication: Korea (South) NLM ID: 101189416 Publication Model: Print Cited Medium: Internet ISSN: 2233-6869 (Electronic) Linking ISSN: 15989992 NLM ISO Abbreviation: Korean J Gastroenterol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Seoul, Korea : Korean Society of Gastroenterology, [2003]-
    • Subject Terms:
      Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use ; Crohn Disease/*drug therapy; Budesonide/therapeutic use ; Crohn Disease/diagnosis ; Crohn Disease/pathology ; Crohn Disease/surgery ; Humans ; Infliximab/therapeutic use ; Mercaptopurine/therapeutic use ; Mesalamine/therapeutic use ; Methotrexate/therapeutic use ; Prednisolone/therapeutic use ; Severity of Illness Index ; Tumor Necrosis Factor-alpha/immunology
    • Abstract:
      Crohn's disease (CD) is a chronic, progressive, and disabling inflammatory bowel disease (IBD) with an uncertain etiopathogenesis. CD can involve any site of the gastrointestinal tract from the mouth to the anus, and is associated with serious complications, such as bowel strictures, perforations, and fistula formation. The incidence and prevalence rates of CD in Korea are still lower compared with those in Western countries, but they have been rapidly increasing during the recent decades. Although there are no definitive curative modalities for CD, various medical and surgical therapies have been applied for the treatment of this disease. Concerning CD management, there have been substantial discrepancies among clinicians according to their personal experience and preference. To suggest recommendable approaches to the diverse problems of CD and to minimize the variations in treatment among physicians, guidelines for the management of CD were first published in 2012 by the IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. These are the revised guidelines based on updated evidence, accumulated since 2012. These guidelines were developed by using mainly adaptation methods, and encompass induction and maintenance treatment of CD, treatment based on disease location, treatment of CD complications, including stricture and fistula, surgical treatment, and prevention of postoperative recurrence. These are the second Korean guidelines for the management of CD and will be continuously revised as new evidence is collected.
    • Contributed Indexing:
      Keywords: Crohn's disease; Guidelines; Treatment
    • Accession Number:
      0 (Anti-Inflammatory Agents, Non-Steroidal)
      0 (Tumor Necrosis Factor-alpha)
      4Q81I59GXC (Mesalamine)
      51333-22-3 (Budesonide)
      9PHQ9Y1OLM (Prednisolone)
      B72HH48FLU (Infliximab)
      E7WED276I5 (Mercaptopurine)
      YL5FZ2Y5U1 (Methotrexate)
    • Publication Date:
      Date Created: 20170201 Date Completed: 20170524 Latest Revision: 20171116
    • Publication Date:
      20231215
    • Accession Number:
      10.4166/kjg.2017.69.1.29
    • Accession Number:
      28135790